TidalSense: Venture Capital Funding History

TidalSense is an AI-powered respiratory diagnostics company headquartered in Cambridge, UK, led by CEO Dr Ameera Patel. Its software device, N-Tidal Diagnose used in combination with N-Tidal hardware, uses AI-analysed tidal breathing — rather than the forced exhalation required by spirometry — to deliver a fast, non-invasive diagnosis of COPD in under five minutes, without specialist training or hospital-grade equipment. N-Tidal Diagnose is the first non-spirometry AI diagnostic device to receive a CE mark under EU MDR (class IIa) for COPD, and has been commissioned and used across multiple healthcare settings.

TidalSense secures £14m in funding from VCs to roll out AI-driven breath test for lung disease

TidalSense is a respiratory diagnostics business in Cambridge that has developed N-Tidal Diagnose, a handheld device and software combination which records a patient breathing normally for 75 seconds and applies AI models to detect chronic obstructive pulmonary disease. Intended for use in primary and community care by any trained healthcare professional, N-Tidal Diagnose removes the need for the forced exhalation and specialist supervision that conventional lung function testing requires.

News from TidalSense

TidalSense secures £14m in funding from VCs to roll out AI-driven breath test for lung disease

More venture news

Stride raises a £4.6m seed round led by Arāya Ventures to offer diagnostics-driven preventative health memberships

Log my Care secures £2m in venture debt from Palatine Growth Credit to provide the care sector with digital management software

Scarlet unlocks a £40m Series B led by Headline for AI-native certification of medical software and devices